Science

Feb 4, 2025, 14:21

Myeloma Paper of the Day, February 4th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of the efficacy of isatuximab, pomalidomide, and dexamethasone in patients with multiple myeloma refractory to daratumumab finds median PFS of 5.8 months (12-month PFS 30.6%); Hb <11.8 g/L predicted 3.5x increased risk of progression, high risk FISH was 10x.”

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

Authors: Enrica Antonia Martino et al.

More posts featuring Robert Orlowski.

cancer dexamethasone Enrica Antonia Martino Isatuximab MD Anderson Cancer Center Myeloma Paper of the Day OncoDaily Oncology Pomalidomide Robert Orlowski

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Special Coverage